Tirzepatide vs Melanotan II
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
TirzepatideSexual Health & Libido
Melanotan II- Summary
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that stimulates melanin production (skin tanning), suppresses appetite, and enhances sexual function. It is not FDA-approved and has significant safety concerns including mole changes and cardiovascular effects.
- Half-Life
- ~5 days
- 1–2 hours
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- 0.25–0.5 mg
- Frequency
- Once weekly, subcutaneous
- Once daily
- Key Benefits
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Promotes skin tanning and melanin production
- Reduces UV exposure needed to tan
- Enhances libido and sexual function
- May suppress appetite
- Faster, deeper tan development
- Longer-lasting tan maintenance
- Potential photoprotective effects
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Nausea (very common, especially in first days)
- Facial flushing
- Spontaneous erections in men
- Darkening or changes in existing moles (monitor closely)
- +3 more
- Stacks With
- —
- —